November 2024
Sarepta Discontinues Development of SRP-5051 for Duchenne Muscular Dystrophy Due to Safety Concerns
Sarepta Therapeutics, SRP-5051, Duchenne muscular dystrophy, DMD, safety concerns, hypomagnesemia, FDA, clinical trials
Genmab Streamlines Portfolio by Cutting Early-Stage Oncology Assets
Genmab, oncology, early-stage candidates, portfolio optimization, Phase 3 projects
Sarepta Therapeutics Halts Development of Vesleteplirsen, a Next-Generation Exon-Skipping Therapy for Duchenne Muscular Dystrophy
Sarepta Therapeutics, Vesleteplirsen (SRP-5051), Duchenne Muscular Dystrophy (DMD), Exon-Skipping Therapy, FDA Feedback, Therapeutic Landscape
Genmab Streamlines Operations by Cutting 3 Early-Stage Programs to Boost Phase 3 Pipeline
Genmab, biotech, clinical programs, phase 3 pipeline, strategic focus
Coherus Resumes Biosimilar Supply Following Temporary Disruption; Novavax Terminates COVID-19 Vaccine Deal with UK
Coherus BioSciences, Biosimilar supply, UDENYCA, Supply chain issues, Novavax, COVID-19 vaccine deal, UK
Nektar Therapeutics Sells Alabama Manufacturing Facility and Reagent Business for $90 Million
Nektar Therapeutics, manufacturing site, reagent arm, divestment, Ampersand, $90 million
Catalent Misses Revenue Estimates Amid Growing Opposition to Novo Holdings’ $16.5 Billion Acquisition
Catalent, Novo Holdings, Acquisition, Revenue Estimates, Pharmaceutical Market, Competition, FTC, Antitrust
Gilead Exceeds COVID-19 Drug Sales Projections, Faces $1.75 Billion Loss on Trodelvy Trial Failure
Gilead, COVID-19, Veklury, Trodelvy, drug sales, clinical trial failure
Arcus Biosciences Reveals Positive Data from Terminated TIGIT Combo Trial, Supporting Future Development
Arcus Biosciences, TIGIT combo, domvanalimab, zimberelimab, cancer treatment, clinical trials
Advancements in Bispecific Antibody Therapies: Recent Deals and Clinical Data on VEGF-Targeting Agents
Bispecific antibodies, VEGF, neovascular age-related macular degeneration (nAMD), cancer therapy, clinical trials, royalty agreements.